GlassScriptPhysician profile
Elina Yushuvayev
NPI 1093002339
$8,007.24
in general payments reported to CMS, 2019-2025
31 companies · $2,149 in 2025
The $2,149 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,614 · 2020: $692 · 2021: $123 · 2022: $78.55 · 2023: $1,217 · 2024: $2,134 · 2025: $2,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,500.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,738.07 | 2019-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $868.20 | 2023-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $755.01 | 2024-2025 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $618.70 | 2023-2024 | Jardiance |
| Genzyme Corporation | $469.30 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $460.99 | 2019-2024 | Cycloset |
| Novo Nordisk INC | $453.65 | 2019-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $433.60 | 2019-2025 | |
| Optinose US, INC. | $367.71 | 2019 | |
| Sunovion Pharmaceuticals INC. | $235.49 | 2019 | |
| Janssen Pharmaceuticals, INC | $218.52 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $179.35 | 2024-2025 | Purified Cortrophin Gel |
| Avanir Pharmaceuticals, INC. | $148.65 | 2019-2020 | |
| Lilly USA, LLC | $148.37 | 2019-2025 | Mounjaro |
| Neos Therapeutics, LP | $146.61 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $128.85 | 2019 | |
| Alkermes, INC. | $125.00 | 2024 | Lybalvi |
| Amarin Pharma, INC. | $120.41 | 2019-2020 | |
| Cequr Corporation | $114.78 | 2024 | Cequr Simplicity |
| Indivior INC. | $48.52 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $43.59 | 2019-2020 | |
| Astellas Pharma US INC | $28.09 | 2025 | Veozah |
| Regeneron Healthcare Solutions, INC. | $25.44 | 2020 | |
| Ibsa Pharma INC. | $21.61 | 2020 | |
| Axsome Therapeutics, INC. | $20.66 | 2025 | Symbravo |
| Horizon Therapeutics Plc | $18.81 | 2022 | |
| Arbor Pharmaceuticals, INC. | $16.49 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.72 | 2019 | |
| Sanofi Pasteur INC. | $14.32 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.70 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $11.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elina Yushuvayev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.